News · eGov
The IISc Bengaluru spin-out has closed a $2.7 million pre-seed round to expand its Venom Atlas dataset and advance AI-driven discovery of therapeutic molecules from animal venoms.
✦ AI SUMMARY 30-second read
- Pre-seed round of $2.7 million co-led by Speciale Invest and South Park Commons, with Operators Studio also participating.
- Funds will expand the Venom Atlas molecular dataset and strengthen AI, laboratory screening, and multidisciplinary hiring.
- The company has joined the NVIDIA Inception programme and was named a Top 5 finalist for the 2026 Indo-Boston Biotech Bridge Award.
Why it matters: India's venom biodiversity could become a source of globally significant medicines if Venomics AI's platform scales as intended.
This summary was generated by AI. Editors may review and update it.
Venomics AI, a biotechnology company that originated from the Indian Institute of Science in Bengaluru, has secured $2.7 million in its first institutional funding round. The pre-seed investment was co-led by Speciale Invest and South Park Commons, with additional participation from Operators Studio.
The company works at the intersection of venom biology, artificial intelligence, and experimental screening to identify and develop molecules derived from animal venoms into therapeutic leads.
What was announced
The capital raised will be deployed across several priorities: expanding the Venom Atlas, which is Venomics AI's proprietary molecular dataset; strengthening its AI modelling and laboratory screening capabilities; and growing its team across venom biology, computational science, and drug discovery.
Funding will also support the validation and optimisation of molecules that show early promise within the platform.
How the platform works
Animal venoms contain a wide variety of molecules that have been refined over millions of years of evolution to act on specific biological targets. Venomics AI uses molecular sequencing and venom biology to build the Venom Atlas, then applies AI to rank and prioritise candidate molecules before testing predictions through functional laboratory screening.
Experimental results from the laboratory feed back into the company's computational models, refining subsequent predictions and informing molecular design. This loop connects in-silico discovery with direct evidence of how molecules behave.
The potential of venom-derived compounds in medicine is not new: captopril, which drew on insights from snake venom peptides, and ziconotide, derived from a cone snail venom peptide, are established examples. Venomics AI aims to explore the much larger portion of venom molecular diversity that remains uncharacterised.
Background and recognition
Venomics AI has established the initial architecture of its discovery platform and has been accepted into the NVIDIA Inception programme, which supports early-stage technology companies. The company was also selected as one of the Top 5 finalists for the 2026 Indo-Boston Biotech Bridge Award.
The company positions its work as combining India's venom biodiversity with domestic scientific and computational expertise to build a drug discovery platform aimed at global therapeutic development.
What happens next
With pre-seed capital now secured, Venomics AI is expected to advance platform development, grow its multidisciplinary team, and progress candidate molecules toward validation. Elets will update this story as further milestones are reached.